Compounds of the general formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

An alkoxy amine compound is provided, which has a chemical structure of:

##STR00001##

wherein each of R.sup.1 is independently H, C.sub.1-6 alkyl group, or C.sub.1-6 alkoxy group; R.sup.2 is C.sub.1-6 alkyl group, R.sup.3 is (C.sub.xH.sub.2x)OH or (C.sub.xH.sub.2x+1), and x is 1 to 8; R.sup.4 is H or C.sub.1-6 alkyl group; R.sup.5 is

##STR00002##

and R.sup.6 is H or C.sub.1-8 alkyl group; R.sup.7 is H or C.sub.1-6 alkyl group, R.sup.8 is

##STR00003##

Ini is a residual group of a radical initiator; and n is an integer of 1 to 10000.

The present invention relates to a phosphinated poly(2,6-dimethy phenylene oxide)oligomer, specifically an unsaturated group-containing phosphinated poly(2,6-dimethy phenylene oxide)oligomer, and processes for producing the same. A thermoset produced from the unsaturated group-containing phosphinated poly(2,6-dimethy phenylene oxide)oligomers according to the present invention exhibits flame retardancy and has a low dielectric constant and dissipation factor and a high glass transition temperature.

Compounds of the general formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.

Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

The present invention relates to Compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.

##STR00001##

The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.

Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver. Novel prodrug compounds of acid/alcohol derivatives such as phosphates, phosphonates, phosphonamidates, phosphoramidates, carboxylates, phenolates, and alkoxylates, their preparation and their uses are described. Some of the novel prodrug compounds described herein do not generate a vinyl keto reactive intermediate in the activation process. Another aspect includes the use of prodrugs to treat diseases that benefit from enhanced drug distribution to the liver and like tissues and cells.

This disclosure relates to uridine di phosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P.sub.2Y.sub.6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.